Virginia Judge Strikes Down Biden Mifepristone Rule

9 sourcesUpdated Jul 24, 2026

A Virginia federal judge, U.S. District Judge Robert Ballou, ruled that the Biden administration's rule requiring doctors and pharmacies to obtain special certification to prescribe mifepristone was not adequately justified and must be reevaluated. The court ordered the FDA to reassess the licensing requirements as part of its ongoing review of mifepristone's safety. The decision aligns with a broader set of legal challenges to abortion-related regulations and reflects ongoing tensions between regulatory oversight and reproductive rights. Attorneys for abortion providers argued the licensing rule imposed burdens without sufficient evidence of need, while the ruling signals potential changes in how abortion medications are accessed and dispensed. The case comes amid intensified political and legal battles over reproductive health policies during the Biden presidency, with Republicans seeking to curb mifepristone access in several states. The rulings across multiple articles underscore the judiciary's pivotal role in shaping the implementation of federal abortion-drug regulations.

In this story:

How it spread

Broke devdiscourse.com · Jul 24, 3:55 PMCenter within the hourLeft +3h9 sources +4h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

How each side headlines it

Left· 2 sources

“Federal Judge Rules FDA Unjustly Restricted Abortion Pill Mifepristone”

Huffington Post · Jul 24, 2026

Center· 1 source

“U.S. Judge Strikes Down Biden-Era Rule That Imposed Restrictions On Prescribing Abortion Drug Mifepriston”

Benzinga · Jul 24, 2026

Right· 0 sources

More on this story

Back to Pulse

Photo: the United States’ — Wikimedia Commons / Wikimedia Commons

LYTENAVA Receives FDA Approval for Wet AMD

Outlook Therapeutics has won FDA approval for LYTENAVA (bevacizumab-vikg), making it the first and only ophthalmic bevacizumab formulation approved for treating wet AMD in the United States and a potential new standard of care developed specifically for the eye. The approval follows a lengthy regulatory history and positions LYTENAVA with anticipated market exclusivity under the BPCIA while signaling a major milestone for retina care.

10 sources

Photo: North America’ — Wikimedia Commons / Wikimedia Commons

Roche cobas BV/CV vaginitis test FDA-cleared

Roche has received FDA 510(k) clearance for the cobas BV/CV assay, which detects bacterial vaginosis and Candida vaginitis from a single vaginal swab using real-time PCR, promising more accurate diagnoses than traditional methods. The test can be run on the cobas platform alongside other sexual-health assays and is intended for professional laboratory use, aiming to reduce misdiagnosis and speed appropriate treatment.